Catalent’s CEO John Chiminski & Endpoints News’ John Carroll discuss their predictions for what 2022 has in store for the biopharma industry.

Summary: Supply chains have come under intense pressure, and companies have had to adapt to this “new normal” to avoid delays. During this Q&A, Catalent discusses....

Summary: During this webinar, we reviewed progress in several areas of advanced development and their impact on readiness for large scale manufacturing.

Summary: Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.

Summary: Join Claudia Berdugo, Ph.D., Director of Process Development at Catalent Biologics, for a podcast where she discusses N-1 perfusion and how Catalent Biologics works toward process improvements....

Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.

Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).

Summary: How can using iPSCs as starting materials help with transforming cell therapies into standard care? This infographic highlights the key features of iPSCs as starting materials, from donor consent through to commercial innovation.

Summary: Experts discuss formulation development and purification strategies to increase throughput, reduce operating costs and decrease...

Summary: In this panel discussion, Endpoints News publisher, Arsalan Arif convenes some of the field's top experts to discuss...